A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).
Phase of Trial: Phase II/III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Generation S2
- Sponsors Novartis Pharmaceuticals
- 02 Apr 2018 Planned End Date changed from 31 Aug 2024 to 30 Aug 2024.
- 02 Apr 2018 Planned primary completion date changed from 31 Aug 2024 to 30 Jul 2024.
- 12 Mar 2018 Planned End Date changed from 30 Jul 2024 to 31 Aug 2024.